title: Pharmacological treatment of benign prostatic hyperplasia with finasteride: a clinical review.
abstract: Finasteride acts by blocking the conversion of testosterone to 5 alpha-dihydrotestosterone, the active androgen metabolite in the human prostate. In large, double-blind, placebo-controlled phase III studies recruiting over 1600 patients, it was shown that the administration of Finasteride, either 5 or 1 mg a day, reduced the size of the prostate by a mean of 22%, following 6 months of therapy. Despite this reduction in prostate size, urinary flow rate only improved by a mean of 1.7 ml per second and symptom score improved only marginally, but statistically significantly different from placebo. Long-term results in small series of patients have indicated a further improvement beyond 1 year. After 3 years flow was improved by 60%. The future role for Finasteride therapy is emerging, but it appears as if patients with mild to moderate symptoms would be a group who could benefit the most. Whether or not Finasteride can stop the long-term natural course of benign prostatic hyperplasia has still to be demonstrated.
authors.affiliation: Department of Urology, Karolinska Hospital, Stockholm, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Ekman
mesh_terms: D017326:Clinical Trials, Phase III as Topic; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
chemical_list: D018120:Finasteride